Initial Public Offering
Baird served as a co-manager in this offering
AboutEndocyte, Inc. (NASDAQ: ECYT) (“Endocyte” or the “Company”) recently completed an initial public offering of 14,375,000 shares of its common stock at a price of $6.00 per share, including the over-allotment option by the underwriters of 1,875,000 shares. All the shares offered were sold by the Company. Including proceeds from the over-allotment option, net proceeds to Endocyte from the initial public offering are $78.8 million. The Company intends to use the net proceeds from this offering to fund its phase 3 clinical trial related to the use of EC145 and EC20 in ovarian cancer and to move preclinical products forward in the development process. The remainder of the net proceeds will be used for working capital and other generate corporate purposes.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
For additional information about this transaction, please contact:
- February 2011
- Endocyte, Inc.
- Target Location
- North America